IN2014CN00572A - - Google Patents

Info

Publication number
IN2014CN00572A
IN2014CN00572A IN572CHN2014A IN2014CN00572A IN 2014CN00572 A IN2014CN00572 A IN 2014CN00572A IN 572CHN2014 A IN572CHN2014 A IN 572CHN2014A IN 2014CN00572 A IN2014CN00572 A IN 2014CN00572A
Authority
IN
India
Prior art keywords
compounds
infections
salts
treating
formula
Prior art date
Application number
Inventor
Pek Yoke Chong
John F Miller
Andrew James Peat
John Brad Shotwell
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47746761&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2014CN00572(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of IN2014CN00572A publication Critical patent/IN2014CN00572A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D307/85—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
    • C07F5/02—Boron compounds
    • C07F5/027—Organoboranes and organoborohydrides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
    • C07F5/02—Boron compounds
    • C07F5/04—Esters of boric acids

Abstract

The present invention features compounds of formula (I) and salts thereof pharmaceutical compositions comprising said compounds and uses of such compounds in treating or preventing viral infections such as HCV infections and diseases associated with such infections.
IN572CHN2014 2011-08-19 2012-08-10 IN2014CN00572A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161525440P 2011-08-19 2011-08-19
US201261650681P 2012-05-23 2012-05-23
PCT/US2012/050268 WO2013028371A1 (en) 2011-08-19 2012-08-10 Benzofuran compounds for the treatment of hepatitis c virus infections

Publications (1)

Publication Number Publication Date
IN2014CN00572A true IN2014CN00572A (en) 2015-04-03

Family

ID=47746761

Family Applications (1)

Application Number Title Priority Date Filing Date
IN572CHN2014 IN2014CN00572A (en) 2011-08-19 2012-08-10

Country Status (37)

Country Link
US (2) US8927593B2 (en)
EP (2) EP2744332B1 (en)
JP (2) JP6367712B2 (en)
KR (1) KR101913800B1 (en)
CN (1) CN103732065B (en)
AR (1) AR087563A1 (en)
AU (1) AU2012299295B2 (en)
BR (1) BR112014002845A2 (en)
CA (1) CA2844086A1 (en)
CL (2) CL2014000393A1 (en)
CO (1) CO6862153A2 (en)
CR (1) CR20140078A (en)
CY (1) CY1118399T1 (en)
DK (1) DK2744332T3 (en)
DO (1) DOP2014000034A (en)
EA (1) EA032841B1 (en)
ES (1) ES2611731T3 (en)
HR (1) HRP20161743T1 (en)
HU (1) HUE030300T2 (en)
IL (1) IL230487B (en)
IN (1) IN2014CN00572A (en)
JO (1) JO3281B1 (en)
LT (1) LT2744332T (en)
MA (1) MA35443B1 (en)
ME (1) ME02588B (en)
MX (1) MX354676B (en)
PE (1) PE20141201A1 (en)
PL (1) PL2744332T3 (en)
PT (1) PT2744332T (en)
RS (1) RS55462B1 (en)
SG (1) SG10201606883QA (en)
SI (1) SI2744332T1 (en)
SM (1) SMT201700028B (en)
TW (1) TWI538915B (en)
UY (1) UY34274A (en)
WO (1) WO2013028371A1 (en)
ZA (1) ZA201401020B (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20141391A1 (en) * 2011-08-17 2014-10-29 Glaxosmithkline Llc COMBINATION THAT INCLUDES A COMPOUND WITH ANTIVIRAL ACTIVITY AND A THERAPEUTIC AGENT
DK2744332T3 (en) 2011-08-19 2017-01-16 Glaxo Group Ltd BENZOFURAN COMPOUNDS FOR TREATMENT OF HEPATITIS C VIRUS INFECTIONS
CA2967195A1 (en) * 2014-11-10 2016-05-19 Glaxosmithkline Intellectual Property (No.2) Limited Long acting pharmaceutical compositions for hepatitis c
EP3218486A1 (en) 2014-11-10 2017-09-20 Glaxosmithkline Intellectual Property (No. 2) Limited Combination long acting compositions and methods for hepatitis c
KR20180006522A (en) 2016-07-07 2018-01-18 삼성디스플레이 주식회사 Liquid crystal composition and liquid crystal display including the same
US11738088B2 (en) 2016-08-01 2023-08-29 University of Pittsburgh—of the Commonwealth System of Higher Education Boryl ethers, carbonates, and cyclic acetals as oxidatively-triggered drug delivery vehicles
US11078170B2 (en) * 2017-03-02 2021-08-03 Assembly Biosciences, Inc. Cyclic sulfamide compounds and methods of using same
UY38051A (en) * 2018-01-17 2019-08-30 Glaxosmithkline Ip Dev Ltd PI4KIIIß INHIBITORS
AU2020371404A1 (en) * 2019-10-25 2022-05-19 Sumitomo Pharma Co., Ltd. Novel substituted condensed ring compound
CN111026203B (en) * 2019-12-02 2021-01-26 宁波德晶元科技有限公司 Heating control method and system suitable for vacuum kettle

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6083903A (en) 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
AU5788800A (en) * 1999-07-07 2001-01-22 Du Pont Pharmaceuticals Company Peptide boronic acid inhibitors of hepatitis c virus protease
AU2002243646B2 (en) 2001-01-25 2006-06-22 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Formulation of boronic acid compounds
KR20050065661A (en) * 2002-11-01 2005-06-29 비로파마 인코포레이티드 Benzofuran compounds, compositions and methods for treatment and prophylaxis of hepatitis c viral infections and associated diseases
CA2631024A1 (en) * 2005-12-01 2008-05-02 Wyeth Anthranilic acid derivatives useful in treating infection with hepatitis c virus
ES2728455T3 (en) 2006-02-16 2019-10-24 Anacor Pharmaceuticals Inc Small molecules containing boron as anti-inflammatory agents
EP2015757A4 (en) * 2006-05-02 2011-01-26 Anacor Pharmaceuticals Inc Hydrolytically-resistant boron-containing therapeutics and methods of use
US20070286822A1 (en) 2006-06-12 2007-12-13 Anacor Pharmaceuticals Inc. Compounds for the Treatment of Periodontal Disease
US7858666B2 (en) * 2007-06-08 2010-12-28 Mannkind Corporation IRE-1α inhibitors
GB0719366D0 (en) * 2007-10-03 2007-11-14 Smithkline Beecham Corp Compounds
WO2009101022A1 (en) * 2008-02-14 2009-08-20 F. Hoffmann-La Roche Ag Heterocyclic antiviral compounds
EP2187893A4 (en) 2008-03-06 2012-02-22 Anacor Pharmaceuticals Inc Boron-containing small molecules as anti-inflammatory agents
WO2009137500A1 (en) * 2008-05-05 2009-11-12 Wyeth 6-substituted benzofuran compounds to treat infection with hepatitis c virus
WO2009137493A1 (en) 2008-05-05 2009-11-12 Wyeth 2-substituted benzofuran compounds to treat infection with hepatitis c virus
TW201008933A (en) 2008-08-29 2010-03-01 Hutchison Medipharma Entpr Ltd Pyrimidine compounds
EP2348863A4 (en) 2008-09-04 2012-03-07 Anacor Pharmaceuticals Inc Boron-containing small molecules
WO2011050284A1 (en) * 2009-10-23 2011-04-28 Glaxosmithkline Llc Pyrazolylpyridine antiviral agents
WO2011103063A1 (en) 2010-02-19 2011-08-25 Glaxo Group Limited Therapeutic compounds
AR080433A1 (en) 2010-03-02 2012-04-11 Merck Sharp & Dohme USEFUL BENZOFURANCARBOXAMIDS DERIVATIVES TO TREAT OR PREVENT HCV INFECTIONS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
WO2011106929A1 (en) 2010-03-02 2011-09-09 Merck Sharp & Dohme Corp. Inhibitors of hepatitis c virus ns5b polymerase
WO2011106986A1 (en) 2010-03-02 2011-09-09 Merck Sharp & Dohme Corp. Inhibitors of hepatitis c virus ns5b polymerase
TW201221131A (en) * 2010-11-18 2012-06-01 Glaxo Group Ltd Compounds
TW201221518A (en) 2010-11-18 2012-06-01 Glaxo Group Ltd Compounds
WO2013025975A1 (en) * 2011-08-17 2013-02-21 Glaxosmithkline Llc Combination treatments for hepatitis c
PE20141391A1 (en) * 2011-08-17 2014-10-29 Glaxosmithkline Llc COMBINATION THAT INCLUDES A COMPOUND WITH ANTIVIRAL ACTIVITY AND A THERAPEUTIC AGENT
DK2744332T3 (en) 2011-08-19 2017-01-16 Glaxo Group Ltd BENZOFURAN COMPOUNDS FOR TREATMENT OF HEPATITIS C VIRUS INFECTIONS

Also Published As

Publication number Publication date
US9682999B2 (en) 2017-06-20
US8927593B2 (en) 2015-01-06
CL2017000293A1 (en) 2017-10-06
HRP20161743T1 (en) 2017-02-24
EP2744332A1 (en) 2014-06-25
MA35443B1 (en) 2014-09-01
AU2012299295A1 (en) 2014-02-20
EA201490213A1 (en) 2014-07-30
LT2744332T (en) 2017-01-10
RS55462B1 (en) 2017-04-28
BR112014002845A2 (en) 2017-02-21
AU2012299295B2 (en) 2016-03-31
HUE030300T2 (en) 2017-04-28
CY1118399T1 (en) 2017-06-28
IL230487B (en) 2019-06-30
UY34274A (en) 2013-04-05
PL2744332T3 (en) 2017-03-31
EP3199531A1 (en) 2017-08-02
TW201321390A (en) 2013-06-01
EP2744332B1 (en) 2016-10-26
US20130237501A1 (en) 2013-09-12
DK2744332T3 (en) 2017-01-16
KR101913800B1 (en) 2018-11-01
EA032841B1 (en) 2019-07-31
PE20141201A1 (en) 2014-10-03
CN103732065A (en) 2014-04-16
JP2017125010A (en) 2017-07-20
KR20140054287A (en) 2014-05-08
CR20140078A (en) 2014-03-20
TWI538915B (en) 2016-06-21
PT2744332T (en) 2017-01-24
CN103732065B (en) 2016-10-26
MX354676B (en) 2018-03-15
ES2611731T3 (en) 2017-05-10
SMT201700028B (en) 2017-03-08
AR087563A1 (en) 2014-04-03
JO3281B1 (en) 2018-09-16
CL2014000393A1 (en) 2014-08-01
JP2014527529A (en) 2014-10-16
EP2744332A4 (en) 2015-01-14
ZA201401020B (en) 2020-11-25
ME02588B (en) 2017-06-20
CO6862153A2 (en) 2014-02-10
SG10201606883QA (en) 2016-10-28
US20150080343A1 (en) 2015-03-19
MX2014001989A (en) 2014-02-27
DOP2014000034A (en) 2014-06-01
JP6367712B2 (en) 2018-08-01
IL230487A0 (en) 2014-03-31
SI2744332T1 (en) 2017-01-31
WO2013028371A1 (en) 2013-02-28
CA2844086A1 (en) 2013-02-28

Similar Documents

Publication Publication Date Title
IN2014CN00572A (en)
MY170941A (en) Pyrimidine derivatives for the treatment of viral infections
IN2014MN02652A (en)
IN2014MN02658A (en)
IN2015DN01156A (en)
IN2014MN02657A (en)
PH12015500274A1 (en) Alkylpyrimidine derivatives for the treatment of viral infections and further diseases
IN2014MN00862A (en)
PH12015500713A1 (en) Acylaminopyrimidine derivatives for the treatment of viral infections and further diseases
PH12015500724A1 (en) 1, 2, 4-triazine derivatives for the treatment of viral infections
MX2015011193A (en) Antiviral compounds.
WO2011160024A3 (en) Compounds useful as antiviral agents, compositions, and methods of use
WO2011150190A3 (en) Hcv inhibitor compounds and methods of use thereof
WO2013106689A8 (en) Hcv ns3 protease inhibitors
PH12014502551A1 (en) Oligonucleotide chelate complex-polypeptide compositions and methods
MX2015011198A (en) Antiviral compounds.
BR112014015582A8 (en) antiviral compounds
IN2015DN02109A (en)
MX2015010892A (en) Antiviral compounds.
MX2015010790A (en) N-heteroaryl substituted aniline derivatives as hcv-antivirals.
MX2015011125A (en) Antiviral compounds.
MX2015011126A (en) Antiviral compounds.
CU20140133A7 (en) COMPOSITIONS AND METHODS OF POLYPEPTIDES-OLIGONUCLEOTIDE CHELATE COMPLEX